Publications by authors named "J Wassil"

Claim this Profile
R
Response to Anticipated impact of novel adult-specific pneumococcal conjugate vaccine by Joshi et al.
J M McLaughlin, J Wassil

Vaccine· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2, randomized, blinded, dose-finding, controlled clinical trial to evaluate the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults 65 years and older.
J Wassil, M Sisti, J Fairman, B Rankin, J Clark

Vaccine· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults aged 18 to 64 years: a phase 1/2, double-masked, dose-finding, active-controlled, randomised clinical trial.
James Wassil, Maggie Sisti, Jeff Fairman, Matthew Davis, Carlos Fierro

Lancet Infect Dis· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of human vaccines on bacterial antimicrobial resistance. A review.
Kathrin U Jansen, William C Gruber, Raphael Simon, James Wassil, Annaliesa S Anderson

Environ Chem Lett· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-clinical immunological comparison of a Next-Generation 24-valent pneumococcal conjugate vaccine (VAX-24) using site-specific carrier protein conjugation to the current standard of care (PCV13 and PPV23).
Jeff Fairman, Paresh Agarwal, Sandrine Barbanel, Christopher Behrens, Aym Berges, James Wassil

Vaccine· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis